Trans-Resveratrol vs. Cis-Resveratrol: Why the Form You Take Matters

You've probably heard resveratrol described as the longevity molecule in red wine, the compound that might explain the French Paradox, or the supplement that activates the same pathways as caloric restriction. But walk into a supplement store or scroll through an online marketplace, and you'll find bottles labeled "resveratrol" at wildly different price points, with doses ranging from 50 mg to 1,000 mg, and almost no mention of the fact that not all resveratrol is created equal. The form matters, the purity matters, and the dose that shows up in clinical trials often bears little resemblance to what's on most supplement labels.

Resveratrol's effects depend entirely on which form you're taking and whether your body can actually absorb it. Superpower's baseline panel includes the metabolic and inflammatory markers that determine how well your body handles compounds like resveratrol, including fasting glucose, insulin, and high-sensitivity CRP.

Key Takeaways

• Trans-resveratrol is the biologically active form; cis-resveratrol has minimal activity.
• Oral bioavailability of resveratrol is less than 1% despite 75% absorption.
• Clinical trials typically use 150–1,000 mg daily of trans-resveratrol (2024 systematic review).
• Purity matters more than total milligrams on the label.
• Most resveratrol is rapidly metabolized in the gut and liver.
• Quality supplements specify trans-resveratrol content and purity percentage.
• Resveratrol's effects are dose-dependent and population-specific in human studies.

What Trans-Resveratrol Is, and Why Cis-Resveratrol Doesn't Work the Same Way

Resveratrol is a polyphenol compound produced by certain plants in response to stress, infection, or UV radiation. It exists in two geometric isomers: trans-resveratrol and cis-resveratrol. These are not simply different names for the same molecule. They are distinct three-dimensional structures with profoundly different biological activity.

Trans-resveratrol is the form found in grape skins, Japanese knotweed (Polygonum cuspidatum), and other plant sources. It is the form that has been studied in the vast majority of preclinical and clinical research. The trans configuration allows the molecule to interact with specific cellular targets:

• Sirtuins (particularly SIRT1), which regulate gene expression and DNA repair.
• AMPK, which controls cellular energy homeostasis.
• Inflammatory signaling pathways, including NF-κB.

When researchers talk about resveratrol activating longevity pathways or mimicking caloric restriction, they are referring to trans-resveratrol. Cis-resveratrol, by contrast, shows substantially weaker binding to these targets. In some assays, cis-resveratrol shows almost no activity at all.

This distinction matters because resveratrol supplements can contain varying ratios of trans and cis isomers depending on how the raw material was extracted, processed, and stored. A supplement labeled "resveratrol 500 mg" that contains 50% cis-resveratrol is functionally closer to 250 mg of active compound. If the label does not specify trans-resveratrol content and purity, you have no way of knowing what you're actually taking.

The Bioavailability Problem: Why Absorption Doesn't Equal Effect

Approximately 75% of orally administered resveratrol is absorbed through the intestinal wall. That sounds promising until you measure what actually reaches systemic circulation: less than 1%. The discrepancy occurs because resveratrol undergoes extensive first-pass metabolism in the gut and liver, where it is rapidly converted to sulfate and glucuronide conjugates. These metabolites have different biological properties than the parent compound and are quickly excreted in urine.

Peak plasma concentrations of free resveratrol occur within 30 to 60 minutes after oral dosing, but the levels are low, typically in the nanomolar range even after gram-scale doses. The half-life is short, around 1.5 to 3 hours. Repeated dosing does not lead to meaningful accumulation. This pharmacokinetic profile explains why some clinical trials using resveratrol have shown modest or inconsistent effects despite mechanistically sound hypotheses.

Efforts to improve bioavailability have included:

• Micronized formulations, which reduce particle size to increase surface area and absorption.
• Liposomal delivery, which protects resveratrol from premature metabolism and may enhance tissue delivery.
• Co-administration with piperine (a compound in black pepper that inhibits drug-metabolizing enzymes).

These formulations come at a higher cost, but the trade-off may be worthwhile if the goal is to achieve physiologically relevant concentrations.

What the Clinical Evidence Actually Shows, and What Doses Were Used

Human clinical trials of resveratrol have used doses ranging from 10 mg to 5,000 mg per day, with the majority clustering between 150 mg and 1,000 mg (2024 meta-analysis). The choice of dose reflects a tension between what is mechanistically plausible and what is practically tolerable.

In a randomized, double-blind trial of resveratrol in Alzheimer's disease, participants received escalating doses starting at 500 mg daily and increasing by 500 mg every 13 weeks, reaching a maximum of 2,000 mg per day (2015 rct). The regimen was well tolerated, and biomarkers of neuroinflammation showed modest improvement, though cognitive outcomes were mixed.

Studies in individuals with type 2 diabetes or metabolic syndrome have shown that 150 mg to 1,000 mg daily of trans-resveratrol can reduce fasting glucose, improve insulin sensitivity, and lower markers of inflammation (2022 meta-analysis). Effect sizes are modest but statistically significant in well-designed trials. Importantly, these benefits are most pronounced in populations with baseline metabolic dysfunction. Healthy, insulin-sensitive individuals show little to no improvement in glucose or insulin markers with resveratrol supplementation.

Higher doses do not always produce better outcomes. One trial found that 300 mg per day produced non-significant improvements in several biomarkers, while 1,000 mg per day paradoxically worsened some outcomes, suggesting a U-shaped dose-response curve (2023 meta-analysis). Most trials are small, short in duration (12 to 24 weeks), and conducted in specific clinical populations. Extrapolating findings from diabetic or obese individuals to healthy adults is not straightforward.

How Resveratrol Works: AMPK, Sirtuins, and Metabolic Mimicry

Resveratrol's biological effects are mediated through several interconnected pathways, the most studied of which involve AMPK (AMP-activated protein kinase) and sirtuins, particularly SIRT1. These pathways are central to cellular energy sensing and metabolic adaptation.

AMPK activation

AMPK is a master regulator of cellular energy homeostasis. It is activated when the ratio of AMP to ATP rises, signaling that the cell is energy-depleted. Once activated, AMPK promotes catabolic processes that generate ATP (such as fatty acid oxidation and glucose uptake) and inhibits anabolic processes that consume ATP (such as lipid and protein synthesis). Resveratrol activates AMPK indirectly by inhibiting mitochondrial ATP production, which increases the AMP/ATP ratio. This is the same mechanism by which metformin and exercise activate AMPK, which is why resveratrol is sometimes described as an exercise mimetic.

SIRT1 activation

SIRT1 is a NAD+-dependent deacetylase that regulates gene expression, DNA repair, and mitochondrial biogenesis. It is upregulated during caloric restriction and is thought to mediate some of the longevity benefits observed in calorie-restricted animals. Resveratrol was initially reported to directly activate SIRT1, but subsequent research has shown that the relationship is more complex (2019 non-rct observational study). Resveratrol may enhance SIRT1 activity indirectly by increasing NAD+ availability or by modulating upstream signaling pathways. Regardless of the mechanism, SIRT1 activation leads to deacetylation of target proteins including PGC-1α (a regulator of mitochondrial biogenesis), FOXO transcription factors (which promote stress resistance and autophagy), and p53 (a tumor suppressor).

Resveratrol also inhibits NF-κB, a transcription factor that drives the expression of pro-inflammatory cytokines, and activates Nrf2, which upregulates antioxidant enzymes such as superoxide dismutase and glutathione peroxidase. These effects are relevant to conditions characterized by chronic low-grade inflammation, including metabolic syndrome, cardiovascular disease, and neurodegenerative disorders.

Dose, Form, and Timing: What the Evidence Supports

Choose supplements that specify trans-resveratrol content and purity. A high-quality supplement will state "98% trans-resveratrol" or provide a breakdown of trans versus cis isomers. Avoid products that list only "resveratrol" without further specification. Micronized or liposomal formulations may offer improved bioavailability, though they are more expensive.

Clinical trials have used doses ranging from 150 mg to 2,000 mg per day, with most metabolic and cardiovascular studies clustering around 500 mg to 1,000 mg (2024 meta-analysis). For general health purposes in the absence of specific metabolic dysfunction, 250 mg to 500 mg of trans-resveratrol per day is a reasonable starting point. Individuals with insulin resistance, prediabetes, or elevated inflammatory markers may benefit from higher doses (500 mg to 1,000 mg), though this should be done under medical supervision.

Resveratrol is fat-soluble, and absorption is enhanced when taken with a meal containing dietary fat. Some studies have administered resveratrol with breakfast or dinner to maximize absorption. Splitting the dose (e.g., 250 mg twice daily) may help maintain more stable plasma levels, though the short half-life means that even split dosing will not produce sustained concentrations (2022 meta-analysis).

Resveratrol is often combined with other compounds thought to enhance its effects or target complementary pathways. NMN (nicotinamide mononucleotide) and resveratrol are frequently paired because NMN increases NAD+ availability, which is required for SIRT1 activity. Quercetin, another polyphenol, has been shown to inhibit resveratrol metabolism, potentially increasing bioavailability. Piperine (from black pepper) inhibits glucuronidation and may increase plasma levels of resveratrol, though it also affects the metabolism of many other compounds and should be used cautiously if you are taking prescription medications.

Who Benefits Most, and Who Should Exercise Caution

Individuals with insulin resistance, prediabetes, type 2 diabetes, or metabolic syndrome are most likely to see measurable benefits from resveratrol supplementation. This is consistent with resveratrol's mechanism of action: it activates pathways that are upregulated during metabolic stress, so individuals who are already metabolically stressed see the greatest benefit.

Older adults may also benefit more than younger individuals, as aging is associated with declining mitochondrial function, increased oxidative stress, and reduced SIRT1 activity (2017 rct). However, older adults are also more likely to be taking multiple medications, which increases the risk of drug interactions.

Resveratrol has antiplatelet effects and may slow blood clotting. Individuals taking anticoagulants (such as warfarin) or antiplatelet drugs (such as aspirin or clopidogrel) should use resveratrol cautiously, as the combination may increase the risk of bleeding. Resveratrol also inhibits certain cytochrome P450 enzymes, which are responsible for metabolizing many prescription drugs. This can lead to increased plasma levels of medications metabolized by these enzymes, including some statins, calcium channel blockers, and immunosuppressants.

Pregnant and breastfeeding women should avoid resveratrol supplements due to insufficient safety data. Resveratrol has estrogenic activity in some tissues, and its effects on fetal development and infant health are not well understood.

Testing Your Metabolic Response: What Biomarkers Tell You

Resveratrol's effects on metabolic health can be tracked using a combination of glucose, insulin, lipid, and inflammatory markers. These provide an objective read on whether supplementation is producing measurable changes in your physiology.

Fasting glucose and HbA1c are the most straightforward markers of glucose control. Fasting insulin and HOMA-IR (calculated from fasting glucose and insulin) provide a more sensitive measure of insulin resistance. Improvements in these markers suggest that resveratrol is enhancing insulin sensitivity.

Lipid markers, including LDL cholesterol, HDL cholesterol, and triglycerides, can also shift with resveratrol supplementation, though the magnitude of change is typically modest. Apolipoprotein B (ApoB), which reflects the total number of atherogenic lipoprotein particles, is a more precise marker of cardiovascular risk than LDL cholesterol alone.

High-sensitivity C-reactive protein (hs-CRP) is a marker of systemic inflammation. Resveratrol's anti-inflammatory effects may be reflected in reduced hs-CRP, particularly in individuals with elevated baseline levels. Other inflammatory markers, such as IL-6 and TNF-α, are less commonly measured in routine clinical practice but may be relevant in research or specialized testing contexts.

Testing before and after 8 to 12 weeks of resveratrol supplementation provides a clearer picture of individual response than relying on subjective symptoms alone. Not everyone responds to resveratrol, and the magnitude of response varies based on baseline metabolic status, genetics, and other factors.

Getting a Real Picture of Your Metabolic Baseline

Resveratrol is one of the most studied polyphenols in the supplement space, but its effects are highly context-dependent. Whether it produces meaningful benefits depends on where your glucose, insulin, lipid, and inflammatory markers sit at baseline, and whether your metabolism is primed to respond to AMPK and sirtuin activation. Superpower's 100+ biomarker panel includes the metabolic and inflammatory markers that determine whether resveratrol is likely to be useful for you, including fasting glucose, insulin, HbA1c, lipid fractionation, and hs-CRP. Testing before you supplement transforms a speculative intervention into a data-driven decision, and retesting after 8 to 12 weeks tells you whether the compound is actually working in your body.